SCHEMBL22609336

SCHEMBL22609336

Cc1onc(C(=O)O)c1Nc1ccc(Oc2ccc(C#N)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ IL18 Q14116 1/20 0.48
▸ MAP2K1 Q02750 5/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ SCN9A Q15858 2/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ SCN5A Q14524 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PARP15 Q460N3 1/20 0.40
▸ PARP10 Q53GL7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22609268 0.93 DHODH (0.43) POLBMAPTKDM4ELMNAPKM
SCHEMBL23453717 0.89 DHODH (0.41) POLBPKMALDH1A1KCNH2RXFP1
SCHEMBL23453702 0.83 VNN1 (0.46) POLBMAPTKDM4EMEN1LMNA
SCHEMBL22609316 0.83 DHODH (0.41) POLBMAPTKDM4EMEN1LMNA
SCHEMBL22609264 0.80 RXFP1 (0.43) POLBMAPTMEN1LMNAKMT2A
SCHEMBL23453703 0.79 ALDH1A1 (0.47) POLBALDH1A1KCNH2ALOX15HSD17B10
SCHEMBL22609213 0.77 ALDH1A1 (0.38) MAPTKDM4EMEN1LMNARAB9A
SCHEMBL23453731 0.76 RAPGEF4 (0.41) POLBMAPTKDM4EMEN1LMNA
SCHEMBL23453755 0.74 PTGER4 (0.43) POLBMAPTKDM4EMEN1LMNA
SCHEMBL8375488 0.73 LMNA (0.54) POLBKDM4ELMNAMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS POLB 1927/4885MAPT 2376/4885KDM4E 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback